Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

7.490 -0.330 (-4.22%)
Streaming Delayed Price Updated: 2:31 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 167,222
Open 7.490
Bid (Size) 7.470 (3)
Ask (Size) 7.490 (2)
Prev. Close 7.820
Today's Range 7.310 - 7.631
52wk Range 7.270 - 30.19
Shares Outstanding 199,873,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-39.5%
-39.5%
1 Month
-6.4%
-6.4%
3 Month
-39.5%
-39.5%
6 Month
-54.6%
-54.6%
1 Year
-55.9%
-55.9%

More News

Read More
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Via Benzinga
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
Via InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
The current price of Cullinan Therapeutics, Inc. - Common Stock is 7.490
When was Cullinan Therapeutics, Inc. - Common Stock last traded?
The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 04/03/25 02:31 PM ET
What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 1.50B
How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
Cullinan Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.